Pawan Sinha
Professor
Massachussetts Institute of Technology
From this contributor
Autism as a disorder of prediction in a ‘magical’ world
A struggle to predict what might happen next could account for the multiple, seemingly disparate, symptoms of autism, say Pawan Sinha, Margaret Kjelgaard and Annie Cardinaux.
Autism as a disorder of prediction in a ‘magical’ world
Vision as gateway for understanding autism
Impairments in vision, even if they don’t cause autism, are likely to be manifestations of underlying neural abnormalities, says Pawan Sinha, professor of vision and founder of the humanitarian organization Project Prakash.
Vision as gateway for understanding autism
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.